Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas.
Youngblood MW, Tran AN, Wang W, An S, Scholtens D, Zhang L, O'Shea K, Pokorny JL, Magill ST, Sachdev S, Lukas RV, Ahmed A, Unruh D, Walshon J, McCortney K, Wang Y, Baran A, Sahm F, Aldape K, Chandler JP, David James C, Heimberger AB, Horbinski C.
Youngblood MW, et al. Among authors: baran a.
Neuro Oncol. 2023 Mar 14;25(3):508-519. doi: 10.1093/neuonc/noac206.
Neuro Oncol. 2023.
PMID: 35976058
Free PMC article.